Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. (ZYNE): 3 pipeline candidates · ~13 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.2 months
D/E 0.39 · 0% dilution
Lead: Phase 2/Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Zynerba Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$36.0M
Quarterly Burn
$8.4M
Runway
13.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| zygel | Phase 2/Phase 3 |
| zyn002 - cannabidiol transdermal gel | Phase 2/Phase 3 |
| zyn002 - transdermal gel | Phase 3 |
Frequently asked questions
How many drug candidates are in Zynerba Pharmaceuticals, Inc.'s pipeline?
Zynerba Pharmaceuticals, Inc. (ZYNE) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zynerba Pharmaceuticals, Inc.'s lead drug candidate?
Zynerba Pharmaceuticals, Inc.'s most advanced tracked candidate is zygel (Phase 2/Phase 3) for 22q11.2 deletion syndrome (22q).
What is Zynerba Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zynerba Pharmaceuticals, Inc. has approximately 13.2 months of cash runway.
Who is the CEO of Zynerba Pharmaceuticals, Inc.?
Directors Armando Anido is the chief executive officer of Zynerba Pharmaceuticals, Inc. (ZYNE).
Get the full picture on Zynerba Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.